Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir
- 6 May 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 31 (9), 813-816
- https://doi.org/10.1038/sj.bmt.1703916
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantationBone Marrow Transplantation, 2002
- Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplantsBlood, 2002
- Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantationBlood, 2002
- Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT)Bone Marrow Transplantation, 2002
- Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantationBlood, 2001
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationBlood, 2001
- Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic CancersNew England Journal of Medicine, 2001
- A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemiaBone Marrow Transplantation, 1997
- Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infectionBritish Journal of Haematology, 1991
- Prevention and Treatment of Cytomegalovirus InfectionAnnual Review of Medicine, 1991